Augmentation of host immune responses to cancer: Overcoming the barrier of tumor antigen-specific ant T-cell tolerance

Cancer Journal

Volumn 6, Issue SUPPL. 3, 2000, Pages

  Levitsky, Hyam I ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; BONE MARROW TRANSPLANTATION; CANCER VACCINES; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INTERFERON TYPE II; LUNG; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 0033927142     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (6)

1. Levitsky HI, Montgomery J, Ahmadzadeh M et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-3865.
2. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95:1178-1183.
3. Sotomayor EM, Borrello I, Tubb E et al. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci USA 1999;96:11476-11481.
4. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/mactophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-366.
5. Sotomayor EM, Borrello I, Tubb E et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-787.
6. Borrello I, Rattis FM, Cooke SK et al. Sustaining the graft versus tumor effect through post-transplant immunization with granulocyte macrophage-colony stimulating factor (GM-CSF) producing tumor vaccines. Blood 2000 (in press).